Takara has been granted a patent for methods of depleting target nucleic acids from a collection. The method involves using nucleic acid guided nucleases to selectively separate target nucleic acids. This innovation opens new possibilities in nucleic acid research and diagnostics. GlobalData’s report on Takara gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Takara, Anti-viral antigen-based compositions was a key innovation area identified from patents. Takara's grant share as of February 2024 was 53%. Grant share is based on the ratio of number of grants to total number of patents.
Selective separation of target nucleic acids from a composition
A recently granted patent (Publication Number: US11884963B2) discloses a method for selectively separating target nucleic acids from a composition. The method involves contacting the composition with cleavage-deficient nucleases and guide nucleic acids to form a complex where the guide nucleic acids specifically hybridize with the target nucleic acids. This complex is then separated from the composition, effectively isolating the target nucleic acids from non-target nucleic acids. The patent claims cover various aspects of the method, including the types of target nucleic acids, guide nucleic acids, and cleavage-deficient nucleases used in the process.
The patent details the application of the method to double-stranded nucleic acids, such as cDNA, DNA, and RNA, with specific examples focusing on cDNA transcribed from ribosomal RNAs or mRNA. Additionally, the guide nucleic acids mentioned in the claims can be either RNA or DNA, with specific hybridization targets identified for RNA guides. The cleavage-deficient nucleases utilized in the method include Cas nucleases and Argonaute nucleases, with the option of incorporating tags for complex separation. The patent also outlines a method for producing a composition enriched with target nucleic acids by following a similar process of contacting the composition with cleavage-deficient nucleases and guide nucleic acids to form a complex that is then separated to obtain a composition selectively enriched with the target nucleic acids.
To know more about GlobalData’s detailed insights on Takara, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
